SCHEMBL319968

SCHEMBL319968

COc1ccc(Sc2cc(F)c(S(=O)(=O)N(Cc3ccc(OC)cc3OC)c3nncs3)cc2Cl)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TP53 P04637 2/20 0.33
LMNA P02545 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
SCN9A Q15858 7/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
TSHR P16473 1/20 0.32
HTR2A P28223 1/20 0.31
SLC6A4 P31645 1/20 0.31
KCNH2 Q12809 1/20 0.31
SCN1A P35498 2/20 0.31
SCN8A Q9UQD0 2/20 0.31
NR1I2 O75469 1/20 0.31
SCN1B Q07699 1/20 0.31
SCN5A Q14524 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16223538 0.94 NPC1 (0.33) NPC1RAB9ASMN1; SMN2TP53LMNA
SCHEMBL16223640 0.94 SCN9A (0.35) NPC1RAB9ASMN1; SMN2TP53LMNA
SCHEMBL16223620 0.93 SMN1; SMN2 (0.33) NPC1RAB9ASMN1; SMN2SCN9AKDM4E
SCHEMBL16223540 0.92 THRB (0.33) NPC1RAB9ASMN1; SMN2SCN9AKDM4E
SCHEMBL16223775 0.91 MEN1 (0.34) NPC1RAB9ASMN1; SMN2LMNASCN9A
SCHEMBL16223569 0.91 NPC1 (0.34) NPC1RAB9ASMN1; SMN2LMNASCN9A
SCHEMBL319861 0.89 SCN9A (0.35) NPC1RAB9ASMN1; SMN2LMNASCN9A
SCHEMBL319860 0.88 NPC1 (0.39) NPC1RAB9ASMN1; SMN2SCN9AKDM4E
SCHEMBL16223588 0.87 KDM4E (0.36) NPC1RAB9ASMN1; SMN2LMNASCN9A
SCHEMBL14921743 0.84 SMN1; SMN2 (0.39) NPC1RAB9ASMN1; SMN2TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2590957-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-12 EP disclosed
EP-2590957-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-12 EP disclosed
EP-2590957-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012004714-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed
WO-2012004714-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109696-A1 Chemical Compounds SCN1A, SCN7A, SCN1B NPC1 1808/4885RAB9A 1400/4885SMN1; SMN2 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.